Program
sparsentan
Also written as “Sparsentan”, “PS433540” and “RE-021 (Sparsentan)”.
Its studies are mostly in Glomerulosclerosis, Focal Segmental · Glomerulonephritis, IGA · Hypertension · Proteinuria, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Travere Therapeutics | 72 open or running | phase 4since Oct 9, 2025 | Jun 4, 2012 | Mar 2027phase 4 · NCT07219121 |
| Ligand Pharmaceuticals | 20 open or running | phase 2since Aug 29, 2007 | Aug 29, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2007First study: phase 2 study in HypertensionNew to Ligand PharmaceuticalsLigand Pharmaceuticals · NCT00522925 · 280 enrolled · United States
- Mar 6, 2008Phase 2 study in HypertensionLigand Pharmaceuticals · NCT00635232 · 261 enrolled · United States
- Jun 4, 2012Travere Therapeutics's first study: phase 2 study in Glomerulosclerosis, Focal SegmentalNew to Travere TherapeuticsTravere Therapeutics · NCT01613118 · 109 enrolled · United States, Czechia, Italy
- Apr 3, 2018Phase 3 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT03493685 · 371 enrolled · United States, Argentina, Australia and more
- Nov 27, 2018Phase 3 study in Glomerulonephritis, IGATravere Therapeutics · NCT03762850 · 406 enrolled · United States, Australia, Belgium and more
- Jul 29, 2021Phase 2 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT05003986 · 67 planned · United States, Germany, Italy and more
- Aug 23, 2022Phase 1 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT05562362 · 47 enrolled · United Kingdom
- May 3, 2023Phase 2 study in Glomerulonephritis, IGATravere Therapeutics · NCT05856760 · 48 enrolled · United States, Hong Kong
- Oct 9, 2025Phase 4 study in ProteinuriaTravere Therapeutics · NCT07219121 · 20 enrolled · United States
Ahead
- Mar 2027Primary completion: phase 4 study in ProteinuriaTravere Therapeutics · NCT07219121
- Mar 12, 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT05003986
TargetBeta
“Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07219121Proteinuria · United States | 4 | Active, not recruiting | Travere Therapeutics | Mar 2027 | 20 |
| NCT05856760Glomerulonephritis, IGA · United States, Hong Kong | 2 | Completed | Travere Therapeutics | Oct 14, 2024 | 48 |
| NCT05562362Glomerulosclerosis, Focal Segmental · United Kingdom | 1 | Completed | Travere Therapeutics | Nov 12, 2020 | 47 |
| NCT05003986Glomerulosclerosis, Focal Segmental · United States, Germany, Italy and more | 2 | Recruiting | Travere Therapeutics | Mar 12, 2027 | 67 |
| NCT03762850Glomerulonephritis, IGA · United States, Australia, Belgium and more | 3 | Completed | Travere Therapeutics | Aug 7, 2023 | 406 |
| NCT03493685Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more | 3 | Completed | Travere Therapeutics | Mar 20, 2023 | 371 |
| NCT01613118Glomerulosclerosis, Focal Segmental · United States, Czechia, Italy | 2 | Completed | Travere Therapeutics | Jun 2016 | 109 |
| NCT00635232Hypertension · United States | 2 | Completed | Ligand Pharmaceuticals | Nov 2008 | 261 |
| NCT00522925Hypertension · United States | 2 | Completed | Ligand Pharmaceuticals | Apr 2008 | 280 |
How it is read
Names in the registry
- “Sparsentan”, 5 entries
- “PS433540”, 5 entries
- “sparsentan”, 2 entries
- “RE-021 (Sparsentan)”, 1 entry
- “RE-021, sparsentan”, 1 entry
Conditions, from the studies’ own filings
- Glomerulosclerosis, Focal Segmental, 4 studies
- Glomerulonephritis, IGA, 2 studies
- Hypertension, 2 studies
- Proteinuria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.